Back to top
more

Madrigal Pharmaceuticals (MDGL)

(Delayed Data from NSDQ)

$319.58 USD

319.58
3,056,202

+60.24 (23.23%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $318.00 -1.58 (-0.49%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

    Company News For Jun 4, 2018

    Companies in the news are: MDGL,LULU,ULTA,GM

      Madrigal's NASH Study Data Encouraging, Stock Skyrockets

      Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.

        Company News For June 1, 2018

        Companies In The News are: GM,DG,DLTR,MDGL

          Madrigal Pharmaceuticals (MDGL) Shares March Higher, Can It Continue?

          As of late, it has definitely been a great time to be an investor in Madrigal Pharmaceuticals, Inc. (MDGL)

            Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?

            In want of an approved product in Madrigal's (MDGL) portfolio, investors' entire focus on first-quarter earnings call to revolve around the company's lead pipeline candidate, MGL-3196.

              Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar?

              Style Box ETF report for DWAS

                Madrigal Pharmaceuticals (MDGL) Soars: Stock Adds 6.5% in Session

                Madrigal Pharmaceuticals (MDGL) was a big mover last session, as the company saw its shares rise more than 6% on the day.

                  Madrigal (MDGL) Q4 Earnings: What's in Store for the Stock?

                  Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.

                    Benjamin Rains headshot

                    3 Buy-Ranked Biotech Stocks That Soared in 2017

                    The S&P 500 is up almost 20% in 2017, with the likes of technology giants Nvidia (NVDA) and Amazon (AMZN) helping lift the index to new heights.

                      What's in Store for Madrigal (MDGL) This Earnings Season?

                      Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.